Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Holger Weis
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1
- Beta
- -0.97
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -862.78
Financials
Revenue
$0.00-100.0%Net Income
$-952.0KEBITDA
$-943.0KFree Cash Flow
$-300.0KEPS (diluted)
$-0.41Shares Outstanding (diluted)
2.43M+179.5%Operating Expenses
$952.0KCash & Debt
$124.0KReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $5.0K | $-4.18M | $-2.20 |
| 2024 | $10.0K | $-4.68M | $-2.92 |
| 2023 | $5.0K | $-35.14M | $-21.97 |
| 2022 | $2.92M | $-37.73M | $-25.97 |
| 2021 | $398.0K | $-78.75M | $-53.80 |
| 2020 | $0.00 | $-79.98M | $-56.42 |
| 2019 | $0.00 | $-117.80M | $-158.90 |
| 2018 | $146.0K | $-53.12M | $-55.52 |
| 2017 | $6.39M | $-54.32M | $-59.50 |
| 2016 | $6.86M | $-165.30M | $-190.15 |
| 2015 | $4.33M | $-120.09M | $-143.63 |
| 2014 | $1.37M | $-31.78M | $-47.14 |
| 2013 | $800.0K | $-57.11M | $-99.67 |
| 2012 | $800.0K | $-96.13M | $-183.58 |
Valuation
TCRThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
140+366.67%Social Signal Score
Mentions (3)
- Newsbenzinga.com·22h ago·Negative
Why is Alaunos Therapeutics Stock Trading 200% Higher on Tuesday? Alaunos Therapeutics, Inc. (NASDAQ:TCRT) stock is surging on Tuesday with a massive session volume of 191.48 million compared to the average volume of 826.167 thousand, according to Benzinga Pro data.
View source ↗ - Newsglobenewswire.com·1d ago·Neutral
Alaunos Therapeutics Announces Acquisition of Velaris Therapeutics Acquisition of Velaris and concurrent oversubscribed $350 million private placement positions the Company to deliver multiple proof-of-concept datasets in pulmonary arterial hypertension
View source ↗ - Newsbenzinga.com·26d ago·Negative
Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket Shares of Alaunos Therapeutics Inc (NASDAQ:TCRT) rose sharply in pre-market trading following a Securities and Exchange Commission filing that showed the company approved and adopted its Second Amended and Restated By-Laws, effective immediately.
View source ↗
Earnings
Tue, Nov 17(in 5 weeks)
Consensus estimate $-15.75 per share
Typical surprise +89.1% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Mar 31$-0.40 vs $-3.69beat
- Fri, Nov 14$-0.55 vs $-4.90beat
- Thu, Aug 14$-0.63 vs $-5.33beat
- Thu, May 15$-0.67 vs $-6.44beat
- Mon, Mar 31$-0.46 vs $-4.50beat
Estimates and results for TCRT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TCRT officers and directors.
- Bought
- $1.3m
- Sold
- $41k
5 trades
4 trades
- Vieser Jaimebought
- Postma Robert Wbought
- Postma Robert Wbought
- Vieser Jaimesold
- Vieser Jaimesold
- Boyle Kevin S. Sr.sold
- Postma Robert Wbought
- Vieser Jaimebought
91 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TCRT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.